Advertisement
Original Research| Volume 174, P40-47, October 2022

Safety and efficacy of S-IROX (S-1, irinotecan and oxaliplatin combination therapy) in patients with advanced pancreatic cancer: A multicenter phase 1b dose-escalation and dose-expansion clinical trial

Published:August 12, 2022DOI:https://doi.org/10.1016/j.ejca.2022.06.010
Safety and efficacy of S-IROX (S-1, irinotecan and oxaliplatin combination therapy) in patients with advanced pancreatic cancer: A multicenter phase 1b dose-escalation and dose-expansion clinical trial
Previous ArticleDetection of ALK fusion variants by RNA-based NGS and clinical outcome correlation in NSCLC patients treated with ALK-TKI sequences
Next ArticleComparative efficacy of novel combination strategies for unresectable hepatocellular carcinoma: A network metanalysis of phase III trials

      Highlights

      • •
        Phase 1b trial of S-1, irinotecan, and oxaliplatin in pancreatic cancer.
      • •
        The RD was S-1 80 mg/m2, irinotecan 150 mg/m2, and oxaliplatin 85 mg/m2.
      • •
        The ORR was 51.1%, and PFS and OS were better than those of the historical FOLFIRINOX.

      Abstract

      Background

      This phase 1b trial evaluated the toxicity and efficacy of S-1, irinotecan, and oxaliplatin combination therapy (S-IROX) as first-line chemotherapy in patients with advanced pancreatic cancer (APC).

      Methods

      Patients aged 20–75 years with APC and an Eastern Cooperative Oncology Group performance status of 0 or 1 were eligible to receive escalating doses of S-1 (60 or 80 mg m2·day) on days 1–7, fixed doses of oxaliplatin (85 mg/m2) biweekly, and escalating doses of irinotecan (150, 165, or 180 mg/m2) once every 2 weeks. In the dose-escalation cohort, a 3 + 3 design was used to determine the maximum-tolerated dose (MTD) and explore the recommended dose (RD). A dose-expansion cohort was added to further evaluate the safety and efficacy of the combination. This trial was registered at UMIN-CTR (UMIN000012054).

      Results

      Approximately 47 patients were enrolled, of whom 45 were eligible for the analysis. The MTD was not determined, but the RD was determined to be dose level 1 based on a review of data from each level. Among the 45 patients, the ORR was 51.1% [95% confidence interval (CI), 35.8–66.3%]. The median progression-free survival and median overall survival was 6.9 months (95% CI, 5.1–8.8 months) and 15.8 months (95% CI, 9.8–20.8 months), respectively. Common adverse events included neutropenia, elevated liver enzyme levels, diarrhoea, and nausea.

      Conclusions

      The S-IROX regimen showed promising efficacy with manageable toxicities in Japanese patients with APC. A randomised phase 2/3 trial comparing S-IROX, mFOLFIRINOX, and gemcitabine plus nab-paclitaxel is currently ongoing (jRCTs031190009).

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Siegel R.L.
        • Miller K.D.
        • Jemal A.
        Cancer statistics, 2020.
        Ca Cancer J Clin. 2020; 70: 7-30https://doi.org/10.3322/caac.21590
        View in Article
        • Vincent A.
        • Herman J.
        • Schulick R.
        • Hruban R.H.
        • Goggins M.
        Pancreatic cancer.
        Lancet. 2011; 378: 607-620https://doi.org/10.1016/s0140-6736(10)62307-0
        View in Article
        • Hoff D.D.V.
        • Ramanathan R.K.
        • Borad M.J.
        • Laheru D.A.
        • Smith L.S.
        • Wood T.E.
        • et al.
        Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial.
        J Clin Oncol. 2011; 29: 4548-4554https://doi.org/10.1200/jco.2011.36.5742
        View in Article
        • Ueno H.
        • Ikeda M.
        • Ueno M.
        • Mizuno N.
        • Ioka T.
        • Omuro Y.
        • et al.
        Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer.
        Cancer Chemother Pharmacol. 2016; 77: 595-603https://doi.org/10.1007/s00280-016-2972-3
        View in Article
        • Conroy T.
        • Desseigne F.
        • Ychou M.
        • Bouché O.
        • Guimbaud R.
        • Bécouarn Y.
        • et al.
        FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
        N Engl J Med. 2011; 364: 1817-1825https://doi.org/10.1056/nejmoa1011923
        View in Article
        • Suker M.
        • Beumer B.R.
        • Sadot E.
        • Marthey L.
        • Faris J.E.
        • Mellon E.A.
        • et al.
        FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis.
        Lancet Oncol. 2016; 17: 801-810https://doi.org/10.1016/s1470-2045(16)00172-8
        View in Article
        • Okusaka T.
        • Ikeda M.
        • Fukutomi A.
        • Ioka T.
        • Furuse J.
        • Ohkawa S.
        • et al.
        Phase II study of FOLFIRINOX for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer.
        Cancer Sci. 2014; 105: 1321-1326https://doi.org/10.1111/cas.12501
        View in Article
        • Stein S.M.
        • James E.S.
        • Deng Y.
        • Cong X.
        • Kortmansky J.S.
        • Li J.
        • et al.
        Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer.
        Br J Cancer. 2016; 114: 737-743https://doi.org/10.1038/bjc.2016.45
        View in Article
        • Li X.
        • Ma T.
        • Zhang Q.
        • Chen Y.-G.
        • Guo C.-X.
        • Shen Y.-N.
        • et al.
        Modified-FOLFIRINOX in metastatic pancreatic cancer: a prospective study in Chinese population.
        Cancer Lett. 2017; 406: 22-26https://doi.org/10.1016/j.canlet.2017.07.012
        View in Article
        • Ozaka M.
        • Ishii H.
        • Sato T.
        • Ueno M.
        • Ikeda M.
        • Uesugi K.
        • et al.
        A phase II study of modified FOLFIRINOX for chemotherapy-naïve patients with metastatic pancreatic cancer.
        Cancer Chemother Pharmacol. 2018; 81: 1017-1023https://doi.org/10.1007/s00280-018-3577-9
        View in Article
        • Conroy T.
        • Hammel P.
        • Hebbar M.
        • Abdelghani M.B.
        • Wei A.C.
        • Raoul J.-L.
        • et al.
        FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer.
        N Engl J Med. 2018; 379: 2395-2406https://doi.org/10.1056/nejmoa1809775
        View in Article
        • Cunningham D.
        • Starling N.
        • Rao S.
        • Iveson T.
        • Nicolson M.
        • Coxon F.
        • et al.
        Capecitabine and oxaliplatin for advanced esophagogastric cancer.
        N Engl J Med. 2008; 358: 36-46https://doi.org/10.1056/nejmoa073149
        View in Article
        • Cassidy J.
        • Clarke S.
        • Díaz-Rubio E.
        • Scheithauer W.
        • Figer A.
        • Wong R.
        • et al.
        Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.
        J Clin Oncol. 2008; 26: 2006-2012https://doi.org/10.1200/jco.2007.14.9898
        View in Article
        • Ueno H.
        • Okusaka T.
        • Ikeda M.
        • Takezako Y.
        • Morizane C.
        An early phase II study of S-1 in patients with metastatic pancreatic cancer.
        Oncology. 2005; 68: 171-178https://doi.org/10.1159/000086771
        View in Article
        • Okusaka T.
        • Funakoshi A.
        • Furuse J.
        • Boku N.
        • Yamao K.
        • Ohkawa S.
        • et al.
        A late phase II study of S-1 for metastatic pancreatic cancer.
        Cancer Chemother Pharmacol. 2008; 61: 615-621https://doi.org/10.1007/s00280-007-0514-8
        View in Article
        • Ueno H.
        • Ioka T.
        • Ikeda M.
        • Ohkawa S.
        • Yanagimoto H.
        • Boku N.
        • et al.
        Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.
        J Clin Oncol. 2013; 31: 1640-1648https://doi.org/10.1200/jco.2012.43.3680
        View in Article
        • Yanagimoto H.
        • Satoi S.
        • Sho M.
        • Akahori T.
        • Yamamoto T.
        • Hirooka S.
        • et al.
        Phase I study assessing the feasibility of the triple combination chemotherapy of SOXIRI (S-1/oxaliplatin/irinotecan) in patients with unresectable pancreatic ductal adenocarcinoma.
        Cancer Chemother Pharmacol. 2016; 77: 35-41https://doi.org/10.1007/s00280-015-2928-z
        View in Article
        • Akahori T.
        • Sho M.
        • Yanagimoto H.
        • Satoi S.
        • Nagai M.
        • Nishiwada S.
        • et al.
        Phase II study of the triple combination chemotherapy of SOXIRI (S-1/Oxaliplatin/Irinotecan) in patients with unresectable pancreatic ductal adenocarcinoma.
        Oncol. 2019; 24 (theoncologist.2018-0900): 749-e224https://doi.org/10.1634/theoncologist.2018-0900
        View in Article
        • Ishikawa T.
        • Kawashima H.
        • Ohno E.
        • Matsubara H.
        • Sasaki Y.
        • Achiwa K.
        • et al.
        Randomized phase II study of consecutive-day versus alternate-day treatment with S-1 as second-line chemotherapy in advanced pancreatic cancer.
        Oncology. 2018; 96: 1-7https://doi.org/10.1159/000492388
        View in Article
        • Kawamoto Y.
        • Nakatsumi H.
        • Harada K.
        • Muranaka T.
        • Ishiguro A.
        • Kobayashi Y.
        • et al.
        A phase I trial of oxaliplatin, irinotecan, and S-1 combination therapy (OX-IRIS) as chemotherapy for unresectable pancreatic cancer (HGCSG 1403).
        Oncol. 2021; 26: e1675-e1682https://doi.org/10.1002/onco.13838
        View in Article
        • Muro K.
        • Boku N.
        • Shimada Y.
        • Tsuji A.
        • Sameshima S.
        • Baba H.
        • et al.
        Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
        Lancet Oncol. 2010; 11: 853-860https://doi.org/10.1016/s1470-2045(10)70181-9
        View in Article

      Article info

      Publication history

      Published online: August 12, 2022
      Accepted: June 2, 2022
      Received in revised form: May 27, 2022
      Received: March 6, 2022

      Identification

      DOI: https://doi.org/10.1016/j.ejca.2022.06.010

      Copyright

      © 2022 Elsevier Ltd. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect
      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


      RELX